Skip to main content
NVDA-2.47%AAPL+1.18%GOOGL-0.43%MSFT-0.18%AMZN-0.04%TSM-2.13%SPCX+1.74%AVGO-0.27%META-0.65%TSLA-0.38%SKHY-5.22%MU-3.82%BRK-B-0.01%LLY+0.41%JPM-0.82%AMD-2.64%WMT+0.89%V-0.32%XOM+0.15%ASMLa-3.01%JNJ0.00%INTC-5.77%MA-0.27%0700.HK-1.94%ORCL-2.65%1398.HK+0.79%BAC-0.41%ABBV+0.61%CSCO-0.30%CVX-0.69%COST+0.22%LRCX-4.40%KO+1.35%CAT-1.64%AMAT-2.69%0005.HK-0.78%AP2d-1.98%UNH+0.66%DELL-3.11%HSBA.L-1.42%MS-0.42%PG+0.02%GE-0.24%3988.HK+0.84%1816.HK+0.23%0857.HK-3.26%NFLX+0.09%HD-1.23%GS-0.92%0939.HK+1.66%NZDJPY-2.69%AUDJPY-2.02%CHFJPY-1.71%USDJPY-1.50%GBPJPY-1.49%EURJPY-1.44%CADJPY-1.41%EURNZD+1.31%NZDCAD-1.30%NZDUSD-1.23%GBPNZD+1.21%NZDCHF-1.02%USDNOK+0.96%USDZAR+0.88%EURNOK+0.85%CHFNOK+0.80%EURZAR+0.78%NOKJPY-0.73%AUDNZD+0.70%GBPZAR+0.66%USDSEK+0.65%AUDCAD-0.64%AUDDKK-0.62%USDMXN+0.60%EURAUD+0.60%EURSEK+0.54%AUDUSD-0.53%AUDSGD-0.52%GBPAUD+0.51%CHFSEK+0.49%USDTHB+0.49%GBPTRY+0.41%USDPLN+0.34%GBPHKD+0.32%AUDCHF-0.32%NZDSGD-0.29%GBPMXN-0.28%CADCHF+0.28%EURCHF+0.26%EURPLN+0.23%AUDNOK+0.23%USDCHF+0.22%USDSGD+0.21%GBPCHF+0.20%USDILS+0.16%EURHKD-0.13%PLNJPY-0.11%USDDKK+0.11%USDTRY+0.11%GBPCAD-0.10%EURSGD+0.10%NZDMXN+0.08%EURGBP+0.08%USDCAD-0.07%EURUSD+0.06%USDCNH+0.05%CHFSGD+0.04%USDCOP-0.04%EURCNH-0.04%GBPSGD-0.03%SGDJPY+0.03%EURCAD-0.02%EURCZK0.00%USDHKD0.00%EURDKK0.00%GBPUSD0.00%XPTUSD-4.55%HG1-4.30%XAGUSD-4.25%GAGUSD-4.25%UKOIL+2.75%USOIL+2.44%COFFEE-1.86%XAUUSD-0.88%GAUUSD-0.88%W1-0.85%COCOA-0.70%C1-0.42%BTCUSD-1.50%ETHUSD-1.40%USDTUSD-0.05%XRPUSD-2.26%SOLUSD-1.91%TRXUSDT-0.06%ZECUSDT-6.27%DOGEUSD-2.82%XMRUSDT-1.63%LINKUSD-1.27%XLMUSD-1.99%BCHUSDT-9.63%LTCUSD-1.54%UNIUSD-3.92%HBARUSDT-1.68%TONUSD+24.88%SUIUSD-3.17%TAOUSDT-4.43%AAVEUSD-2.97%DOTUSDT-3.07%ICPUSDT-0.65%ONDOUSDT-2.84%WLDUSDT-2.67%ATOMUSDT-3.03%ARBUSDT+1.71%JUPUSDT-2.96%INJUSDT-3.59%STXUSDT-3.43%FETUSDT-2.98%TIAUSDT-1.13%PYTHUSDT-1.00%SEIUSDT-3.91%IMXUSDT-3.06%WIFUSDT-4.89%GRTUSDT-3.13%OPUSDT-3.00%IOTAUSDT-3.54%POLUSDT-6.59%AXSUSDT-2.47%FARTCOINUSDT-2.79%EOSUSDT-1.18%DYDXUSDT-0.88%ORDIUSDT-0.61%GALAUSDT-4.21%NOTUSDT-2.97%RONINUSDT-2.64%NVDA-2.47%AAPL+1.18%GOOGL-0.43%MSFT-0.18%AMZN-0.04%TSM-2.13%SPCX+1.74%AVGO-0.27%META-0.65%TSLA-0.38%SKHY-5.22%MU-3.82%BRK-B-0.01%LLY+0.41%JPM-0.82%AMD-2.64%WMT+0.89%V-0.32%XOM+0.15%ASMLa-3.01%JNJ0.00%INTC-5.77%MA-0.27%0700.HK-1.94%ORCL-2.65%1398.HK+0.79%BAC-0.41%ABBV+0.61%CSCO-0.30%CVX-0.69%COST+0.22%LRCX-4.40%KO+1.35%CAT-1.64%AMAT-2.69%0005.HK-0.78%AP2d-1.98%UNH+0.66%DELL-3.11%HSBA.L-1.42%MS-0.42%PG+0.02%GE-0.24%3988.HK+0.84%1816.HK+0.23%0857.HK-3.26%NFLX+0.09%HD-1.23%GS-0.92%0939.HK+1.66%NZDJPY-2.69%AUDJPY-2.02%CHFJPY-1.71%USDJPY-1.50%GBPJPY-1.49%EURJPY-1.44%CADJPY-1.41%EURNZD+1.31%NZDCAD-1.30%NZDUSD-1.23%GBPNZD+1.21%NZDCHF-1.02%USDNOK+0.96%USDZAR+0.88%EURNOK+0.85%CHFNOK+0.80%EURZAR+0.78%NOKJPY-0.73%AUDNZD+0.70%GBPZAR+0.66%USDSEK+0.65%AUDCAD-0.64%AUDDKK-0.62%USDMXN+0.60%EURAUD+0.60%EURSEK+0.54%AUDUSD-0.53%AUDSGD-0.52%GBPAUD+0.51%CHFSEK+0.49%USDTHB+0.49%GBPTRY+0.41%USDPLN+0.34%GBPHKD+0.32%AUDCHF-0.32%NZDSGD-0.29%GBPMXN-0.28%CADCHF+0.28%EURCHF+0.26%EURPLN+0.23%AUDNOK+0.23%USDCHF+0.22%USDSGD+0.21%GBPCHF+0.20%USDILS+0.16%EURHKD-0.13%PLNJPY-0.11%USDDKK+0.11%USDTRY+0.11%GBPCAD-0.10%EURSGD+0.10%NZDMXN+0.08%EURGBP+0.08%USDCAD-0.07%EURUSD+0.06%USDCNH+0.05%CHFSGD+0.04%USDCOP-0.04%EURCNH-0.04%GBPSGD-0.03%SGDJPY+0.03%EURCAD-0.02%EURCZK0.00%USDHKD0.00%EURDKK0.00%GBPUSD0.00%XPTUSD-4.55%HG1-4.30%XAGUSD-4.25%GAGUSD-4.25%UKOIL+2.75%USOIL+2.44%COFFEE-1.86%XAUUSD-0.88%GAUUSD-0.88%W1-0.85%COCOA-0.70%C1-0.42%BTCUSD-1.50%ETHUSD-1.40%USDTUSD-0.05%XRPUSD-2.26%SOLUSD-1.91%TRXUSDT-0.06%ZECUSDT-6.27%DOGEUSD-2.82%XMRUSDT-1.63%LINKUSD-1.27%XLMUSD-1.99%BCHUSDT-9.63%LTCUSD-1.54%UNIUSD-3.92%HBARUSDT-1.68%TONUSD+24.88%SUIUSD-3.17%TAOUSDT-4.43%AAVEUSD-2.97%DOTUSDT-3.07%ICPUSDT-0.65%ONDOUSDT-2.84%WLDUSDT-2.67%ATOMUSDT-3.03%ARBUSDT+1.71%JUPUSDT-2.96%INJUSDT-3.59%STXUSDT-3.43%FETUSDT-2.98%TIAUSDT-1.13%PYTHUSDT-1.00%SEIUSDT-3.91%IMXUSDT-3.06%WIFUSDT-4.89%GRTUSDT-3.13%OPUSDT-3.00%IOTAUSDT-3.54%POLUSDT-6.59%AXSUSDT-2.47%FARTCOINUSDT-2.79%EOSUSDT-1.18%DYDXUSDT-0.88%ORDIUSDT-0.61%GALAUSDT-4.21%NOTUSDT-2.97%RONINUSDT-2.64%
CP

Corvus Pharmaceuticals, Inc. (CRVS)

NASDAQ • Healthcare

$13.33
-$0.59 (-4.3%)
Market open

Last close at September 9, 2026 at 20:00 UTC

Open$13.76
Previous Close$13.33
Day Range$12.95 - $13.91
Avg. Volume (3M)736.2K
Market Cap$1.1B
52 Week Range
$5.64$26.95
Next EarningsIn 54 daysNov 3, 2026

Metrics Over Time

Fundamentals & Financials

Revenue (TTM)
$0
Net Income (TTM)
-$54.1M
EPS (TTM)
-$0.64
ROA (TTM)
-22.62%
Current Ratio
16.16

TTM is calculated as the sum of the four most recently completed quarters. This is a standard approach when monthly or real-time data is not available.

Earnings

-7.1%Q1 2026-$0.15
-7.1%Q2 2026-$0.15
-19.4%Q3 2026-$0.19
Next

Nov 3

in 54 daysQ4 2026

% — EPS deviation from the forecast (beat / miss); quarters without a forecast show the reported EPS

View full earnings history

About Corvus Pharmaceuticals, Inc.

Corvus Pharmaceuticals, Inc. is a NASDAQ-listed biotechnology company focused on developing and commercializing immuno-oncology therapies. The company operates as a small-cap drug developer built around antibody and small-molecule candidates, with programs aimed at cancer as well as inflammatory and fibrotic disease pathways.

Name
Corvus Pharmaceuticals, Inc.
CEO
Richard A. Miller
Website
www.corvuspharma.com
Industry
Healthcare
Year Founded
2014
Employees
37

Today's Snapshot

AI-generated

Yesterday CRVS fell 4.3% to 13.33.

Trading Volume

Above 10d avg 751.4K

1M

vs S&P 500 Today

Strong Underperformance

-3.83%

Updated: September 10, 2026 at 12:03 UTC

Technical Indicators

1 Buy2 Neutral5 Sell
CRVS looks weak on momentum and moving-average structure, with the CCI deeply negative and the MACD marginally negative while the RSI sits below neutral, pointing to selling pressure. The price is beneath most short- and medium-term averages and the classic pivot level, ADX is low so the directional trend lacks strength, and OBV signals distribution; volatility is notable relative to price. Meanwhile Bollinger positioning suggests the name is trading toward oversold extremes, which may warrant caution in interpreting bearish signals. Technical takeaway: momentum and MA alignment favor selling, though oversold breadth advises caution.
All signals
  • EMA (5 indicators)$12.93 - $14.25
    Sell
  • RSI (14)39.44
    Neutral
  • Stochastic %K (14, 3, 3)20.29
    Neutral
  • MACD Level (12, 26)-0.06
    Sell

Peers & Related Assets

ABSIAbsci Corporation
$8.65-2.9%
OLMAOlema Pharmaceuticals, Inc.
$10.36-5.7%
VSTMVerastem, Inc.
$7.94-1.7%
PRTAProthena Corporation plc
$9.3-2.5%
RGNXREGENXBIO Inc.
$8.73-0.3%
CMPXCompass Therapeutics, Inc.
$2.18-1.4%
Stay Ahead of the Market

Get premium market insights delivered directly to your inbox.